Article List

1. Gaucher or pseudo‑Gaucher cells	Page:7—
2. Correction: MicroRNA‑765 is upregulated in myelodysplastic syndromes and induces apoptosis via PLP2 inhibition in leukemia cells	Page:20—
3. Correction: Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation	Page:17—
4. Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant‑ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM‑2002 study	Page:24—
5. Preoperative consultation for determining the appropriate transfusion strategy	Page:21—
6. Treatment with ropeginterferon alfa‑2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea:one‑year results from a phase 2 study	Page:23—
7. Acute erythroid leukemia leading to the diagnosis of Schwachman‑Diamond syndrome	Page:10—
8. Rare pseudo‑chediak‑higashi inclusions in a patient with disseminated diffuse large B cell lymphoma	Page:13—
9. Transfusion‑transmitted infections	Page:14—
10. The role of next‑generation sequencing in hematologic malignancies	Page:11—
11. How to improve AML outcomes?	Page:39—
12. Functional iron deficiency anemia in patients with cancer	Page:26—
13. Genomic testing for germline predisposition to hematologic malignancies	Page:12—
14. Absence of canonical mutations in pediatric essential thrombocytosis: a case series	Page:32—
15. Proper application of anticoagulation therapy on cancer‑associated venous thrombosis	Page:25—
16. Monoclonal gammopathy of renal significance from the perspective of nephrologists	Page:28—
17. Advancements in the understanding and management of histiocytic neoplasms	Page:22—
18. Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation	Page:16—
19. Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review	Page:29—
20. Real‑world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors	Page:34—
21. What is new in acute myeloid leukemia classification?	Page:15—
22. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT‑clot waveform analysis	Page:19—
23. Impact of CYP1A1 variants on the risk of acute lymphoblastic leukemia: evidence from an updated meta‑analysis	Page:9—
24. Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology	Page:40—
25. Real‑world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization	Page:30—
26. Cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‑4) gene polymorphismsin a cohort of Egyptian patients with immune thrombocytopenia (ITP)	Page:8—
27. Pathologic characteristics of histiocytic and dendritic cell neoplasms	Page:18—
28. Back to basics: the coagulation pathway	Page:35—
29. Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia‑related genes mutations and TP53 aberrations	Page:41—
30. Prognostic significance and biological implications of SM‑like genes in mantle cell lymphoma	Page:33—
31. Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting	Page:42—
32. Comparable outcomes with low‑dose and standard‑dose horse anti‑thymocyte globulin in the treatment of severe aplastic anemia	Page:6—
33. Clinical data on treatment regimen and use of medication among patients with hemophilia B in Korea	Page:27—
34. Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status:a single‑center database analysis	Page:31—
35. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL:a retrospective analysis	Page:36—
36. Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers	Page:37—
37. Strategies for integrating ChatGPT and generative AI into clinical studies	Page:45—
38. RAD51 and RAD50 genetic polymorphisms from homologous recombination repair pathway are associated with disease outcomes and organ toxicities in AML	Page:46—
39. Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia	Page:44—
40. Bone marrow mesenchymal stem cell exosomes suppress JAK/STAT signaling pathway in acute myeloid leukemia in vitro	Page:43—
41. Gaucher or pseudo‑Gaucher cells	Page:7—
42. Correction: MicroRNA‑765 is upregulated in myelodysplastic syndromes and induces apoptosis via PLP2 inhibition in leukemia cells	Page:20—
43. Correction: Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation	Page:17—
44. Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant‑ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM‑2002 study	Page:24—
45. Preoperative consultation for determining the appropriate transfusion strategy	Page:21—
46. Treatment with ropeginterferon alfa‑2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea:one‑year results from a phase 2 study	Page:23—
47. Acute erythroid leukemia leading to the diagnosis of Schwachman‑Diamond syndrome	Page:10—
48. Rare pseudo‑chediak‑higashi inclusions in a patient with disseminated diffuse large B cell lymphoma	Page:13—
49. Transfusion‑transmitted infections	Page:14—
50. The role of next‑generation sequencing in hematologic malignancies	Page:11—
51. How to improve AML outcomes?	Page:39—
52. Functional iron deficiency anemia in patients with cancer	Page:26—
53. Genomic testing for germline predisposition to hematologic malignancies	Page:12—
54. Absence of canonical mutations in pediatric essential thrombocytosis: a case series	Page:32—
55. Proper application of anticoagulation therapy on cancer‑associated venous thrombosis	Page:25—
56. Monoclonal gammopathy of renal significance from the perspective of nephrologists	Page:28—
57. Advancements in the understanding and management of histiocytic neoplasms	Page:22—
58. Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation	Page:16—
59. Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review	Page:29—
60. Real‑world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors	Page:34—
61. What is new in acute myeloid leukemia classification?	Page:15—
62. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT‑clot waveform analysis	Page:19—
63. Impact of CYP1A1 variants on the risk of acute lymphoblastic leukemia: evidence from an updated meta‑analysis	Page:9—
64. Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology	Page:40—
65. Real‑world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization	Page:30—
66. Cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‑4) gene polymorphismsin a cohort of Egyptian patients with immune thrombocytopenia (ITP)	Page:8—
67. Pathologic characteristics of histiocytic and dendritic cell neoplasms	Page:18—
68. Back to basics: the coagulation pathway	Page:35—
69. Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia‑related genes mutations and TP53 aberrations	Page:41—
70. Prognostic significance and biological implications of SM‑like genes in mantle cell lymphoma	Page:33—
71. Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting	Page:42—
72. Comparable outcomes with low‑dose and standard‑dose horse anti‑thymocyte globulin in the treatment of severe aplastic anemia	Page:6—
73. Clinical data on treatment regimen and use of medication among patients with hemophilia B in Korea	Page:27—
74. Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status:a single‑center database analysis	Page:31—
75. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL:a retrospective analysis	Page:36—
76. Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers	Page:37—
77. Strategies for integrating ChatGPT and generative AI into clinical studies	Page:45—
78. RAD51 and RAD50 genetic polymorphisms from homologous recombination repair pathway are associated with disease outcomes and organ toxicities in AML	Page:46—
79. Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia	Page:44—
80. Bone marrow mesenchymal stem cell exosomes suppress JAK/STAT signaling pathway in acute myeloid leukemia in vitro	Page:43—
81. Gaucher or pseudo‑Gaucher cells	Page:7—
82. Correction: MicroRNA‑765 is upregulated in myelodysplastic syndromes and induces apoptosis via PLP2 inhibition in leukemia cells	Page:20—
83. Correction: Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation	Page:17—
84. Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant‑ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM‑2002 study	Page:24—
85. Preoperative consultation for determining the appropriate transfusion strategy	Page:21—
86. Treatment with ropeginterferon alfa‑2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea:one‑year results from a phase 2 study	Page:23—
87. Acute erythroid leukemia leading to the diagnosis of Schwachman‑Diamond syndrome	Page:10—
88. Rare pseudo‑chediak‑higashi inclusions in a patient with disseminated diffuse large B cell lymphoma	Page:13—
89. Transfusion‑transmitted infections	Page:14—
90. The role of next‑generation sequencing in hematologic malignancies	Page:11—
91. How to improve AML outcomes?	Page:39—
92. Functional iron deficiency anemia in patients with cancer	Page:26—
93. Genomic testing for germline predisposition to hematologic malignancies	Page:12—
94. Absence of canonical mutations in pediatric essential thrombocytosis: a case series	Page:32—
95. Proper application of anticoagulation therapy on cancer‑associated venous thrombosis	Page:25—
96. Monoclonal gammopathy of renal significance from the perspective of nephrologists	Page:28—
97. Advancements in the understanding and management of histiocytic neoplasms	Page:22—
98. Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A:correlation with “Inhibitor” formation	Page:16—
99. Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review	Page:29—
100. Real‑world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors	Page:34—
101. What is new in acute myeloid leukemia classification?	Page:15—
102. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT‑clot waveform analysis	Page:19—
103. Impact of CYP1A1 variants on the risk of acute lymphoblastic leukemia: evidence from an updated meta‑analysis	Page:9—
104. Evaluating histone H3.1 as a biomarker for acute ischemic stroke: insights into NETs and stroke pathophysiology	Page:40—
105. Real‑world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization	Page:30—
106. Cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‑4) gene polymorphismsin a cohort of Egyptian patients with immune thrombocytopenia (ITP)	Page:8—
107. Pathologic characteristics of histiocytic and dendritic cell neoplasms	Page:18—
108. Back to basics: the coagulation pathway	Page:35—
109. Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia‑related genes mutations and TP53 aberrations	Page:41—
110. Prognostic significance and biological implications of SM‑like genes in mantle cell lymphoma	Page:33—
111. Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting	Page:42—
112. Comparable outcomes with low‑dose and standard‑dose horse anti‑thymocyte globulin in the treatment of severe aplastic anemia	Page:6—
113. Clinical data on treatment regimen and use of medication among patients with hemophilia B in Korea	Page:27—
114. Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status:a single‑center database analysis	Page:31—
115. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL:a retrospective analysis	Page:36—
116. Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers	Page:37—
117. Strategies for integrating ChatGPT and generative AI into clinical studies	Page:45—
118. RAD51 and RAD50 genetic polymorphisms from homologous recombination repair pathway are associated with disease outcomes and organ toxicities in AML	Page:46—
119. Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia	Page:44—
120. Bone marrow mesenchymal stem cell exosomes suppress JAK/STAT signaling pathway in acute myeloid leukemia in vitro	Page:43—
121. Peripheral T‑cell lymphoma, NOS in bone marrow and heart	Page:5—
122. Genomic technologies for detecting structural variations in hematologic malignancies	Page:1—
123. Upregulation of lnc‑FOXD2‑AS1, CDC45, and CDK1 in patients with primary non‑M3 AML is associated with a worse prognosis	Page:4—
124. Real‑world incidence and risk factors of bortezomib‑related cardiovascular adverse events in patients with multiple myeloma	Page:3—
125. Adding MYC/BCL2 double expression to NCCN‑IPI may not improve prognostic value to an acceptable level	Page:2—

Volume: 59